Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED Beats Target with Out-Licensing of 162 Drug Candidates in FY2015-FY2018
June 27, 2019
- Set Lower Premiums for Super Pricey Cell, Gene Therapies: Drug Pricing Organization
June 26, 2019
- Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
June 26, 2019
- AMED to Fund Biomarker Development for Anti-PD-1 Antibodies
June 25, 2019
- Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
- Govt Earmarks 3 Billion Yen for AMED's Organ-on-Chip Project
June 21, 2019
- ICH to Discuss Use of RWD in Post-Marketing Safety Measures: Amsterdam Meeting
June 20, 2019
- MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
- MHLW Orders Label Revisions for Metformin, Blanket Contraindication for Patients with Severe Kidney Impairment
June 19, 2019
- Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
- LDP Inscribes AI Utilization for Drug Development in Honebuto Paper
June 19, 2019
- PMDA to Strengthen Grad/Mid-Career Hiring Strategy, Increase Operating Efficiency with AI
June 19, 2019
- 2 PMDA Advisors Infringe COI Rules; No Impact on Product Approvals
June 18, 2019
- PMDA to Prohibit Staffers from Trading Pharma Shares
June 17, 2019
- PMDA to Discuss Optimal Use of Xofluza amid Concerns over Resistant Viruses
June 17, 2019
- 10 More Hospitals to Join MID-NET Database, Covering Data on 6 Million Patients
June 17, 2019
- PMDA Reviewing Risks for Ibrance, Opdivo, Keytruda and More
June 17, 2019
- LDP’s Pharma Study Group Submits Proposal to Health Minister, Calls for PMP Revamp in 2020 Reform
June 13, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Govt’s Draft Policy Blueprint Prods Continued Debates on Pricing Reform Proposals; Expanded HTA Use, Handling of PMP-Granted Comparators and More
June 12, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…